Prasugrel - a promising drug in the treatment of atherothrombotic events

Abstract

Prasugrel, a newly authorized irreversible platelet adenosine diphosphate (ADP) receptor blocker, is an interesting innovation in the range of antithrombotic drugs. It is superior to its predecessor clopidogrel in antiplatelet effect, due to lower resistance and more rapid onset of action.

Prasugrel has been approved for use in patients with acute coronary syndromes scheduled for coronary angioplasty.

Keywords

• ADP receptor inhibitors
• prasugrel
• treatment of acute coronary syndromes